AstraZeneca and Merck’s ovarian cancer drug Lynparza received U.S. regulatory approval for the treatment of advanced pancreatic cancer.
Companies from across the globe provide updates on their business and pipeline progress.
Arcus Biosciences and Roche company Genentech are partnering on two clinical trials for colorectal and pancreatic cancer.
GlaxoSmithKline submitted a Biologics License Application to the U.S. FDA based upon results from the pivotal DREAMM-2 Phase III trial of belantamab mafodotin in multiple myeloma.
A late-stage trial failed to show that BeiGene Ltd.’s cancer treatment Brukinsa was superior to Imbruvica, a rival drug from Johnson & Johnson and AbbVie Inc., for treating WM.
The U.S. Food and Drug Administration approved Pfizer Inc.’s Xeljanz XR (tofacitinib) extended-release 11 mg and 22 mg tablets for the once-daily treatment of adult patients with moderately to severely active ulcerative colitis, after an inadequate response or intolerance to TNF blockers.
Exploratory Analysis Shows Significant OS Results from Keytruda in KRAS Mutations
Blockbusters, Checkpoint Inhibitors, Chemotherapy, Clinical Trials, European Society for Medical Oncology (ESMO), Exploratory Analysis, Keytruda, KRAS Mutations, Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Monotherapy, Overall Response Rate (ORR), Overall Survival (OS), Progression-Free Survival (PFS), R&DFindings from the Phase III KEYNOTE-042 study show improvements in overall survival (OS), PFS and ORR in patients treated with Merck’s Keytruda (pembrolizumab) as a monotherapy.
Merck & Co. Inc. is buying ArQule Inc. for $2.7 billion, seeking to tap into the drug developer’s experimental blood cancer therapy that targets genetic mutations.
ObsEva SA reported positive Phase 3 trial results from the PRIMROSE 2 trial of linzagolix for the treatment of heavy menstrual bleeding (HMB) due to uterine fibroids.
Spain’s Grifols said the latest results from a clinical trial of the company’s Alzheimer’s treatment show positive effects by achieving a reduction of the disease’s progression in patients with mild and moderate conditions.
